BR112018068128A2 - algoritmo e um método in vitro com base em edição de rna para selecionar o efeito particular induzido por compostos ativos - Google Patents

algoritmo e um método in vitro com base em edição de rna para selecionar o efeito particular induzido por compostos ativos

Info

Publication number
BR112018068128A2
BR112018068128A2 BR112018068128A BR112018068128A BR112018068128A2 BR 112018068128 A2 BR112018068128 A2 BR 112018068128A2 BR 112018068128 A BR112018068128 A BR 112018068128A BR 112018068128 A BR112018068128 A BR 112018068128A BR 112018068128 A2 BR112018068128 A2 BR 112018068128A2
Authority
BR
Brazil
Prior art keywords
algorithm
select
method based
active compounds
particular effect
Prior art date
Application number
BR112018068128A
Other languages
English (en)
Inventor
Weissmann Dinah
Molina Franck
Pujol Jean-François
Salvetat Nicolas
Van Der Laan Siem
Original Assignee
Alcediag
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcediag, Centre Nat Rech Scient filed Critical Alcediag
Publication of BR112018068128A2 publication Critical patent/BR112018068128A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a presente invenção refere-se a um algoritmo e método usando o mesmo algoritmo para prognosticar in vitro a probabilidade de um fármaco ou um composto induzir um efeito particular em um paciente, o dito método usando pelo menos um alvo exibindo uma edição a a i de rna. a presente invenção também se refere a kits para a implementação do método.
BR112018068128A 2016-03-11 2017-03-13 algoritmo e um método in vitro com base em edição de rna para selecionar o efeito particular induzido por compostos ativos BR112018068128A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16000600 2016-03-11
PCT/IB2017/000417 WO2017153849A1 (en) 2016-03-11 2017-03-13 Algorithm and an in vitro method based on rna editing to select particular effect induced by active compounds

Publications (1)

Publication Number Publication Date
BR112018068128A2 true BR112018068128A2 (pt) 2019-01-15

Family

ID=55587999

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068128A BR112018068128A2 (pt) 2016-03-11 2017-03-13 algoritmo e um método in vitro com base em edição de rna para selecionar o efeito particular induzido por compostos ativos

Country Status (9)

Country Link
US (1) US20190249251A1 (pt)
EP (1) EP3426801B1 (pt)
JP (2) JP7227006B2 (pt)
CN (1) CN108779494B (pt)
BR (1) BR112018068128A2 (pt)
CA (1) CA3016657A1 (pt)
ES (1) ES2848949T3 (pt)
IL (1) IL261579B2 (pt)
WO (1) WO2017153849A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819386A1 (en) * 2019-11-08 2021-05-12 Alcediag Diagnosing of mood disorders using blood rna editing biomarkers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152146A1 (en) 2007-06-13 2008-12-18 Biocortech Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications
WO2010064231A1 (en) * 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
EP2202321A1 (en) 2008-12-17 2010-06-30 Biocortech Evaluation of the potential risk of drug induced mood disturbance and suicide:use of a dedicated platform
EP2585613B1 (en) 2010-06-24 2021-02-24 Alcediag Editing profiling of pde8a pre -mrna : use as specific biomarker of adars activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
US20150056622A1 (en) * 2013-08-06 2015-02-26 Biocortech Editing profiling of pde8a pre -mrna: use as specific biomarker of adars activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects
WO2013003112A1 (en) 2011-06-27 2013-01-03 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease

Also Published As

Publication number Publication date
JP7227006B2 (ja) 2023-02-21
CN108779494B (zh) 2024-05-14
JP2019515651A (ja) 2019-06-13
IL261579B2 (en) 2023-07-01
EP3426801B1 (en) 2020-10-14
EP3426801A1 (en) 2019-01-16
IL261579B1 (en) 2023-03-01
CA3016657A1 (en) 2017-09-14
CN108779494A (zh) 2018-11-09
WO2017153849A1 (en) 2017-09-14
JP2022134134A (ja) 2022-09-14
IL261579A (en) 2018-10-31
US20190249251A1 (en) 2019-08-15
ES2848949T3 (es) 2021-08-13

Similar Documents

Publication Publication Date Title
BR112018011089A2 (pt) composições e métodos para a imuno-oncologia
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112018012914A2 (pt) composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica
CL2016001101A1 (es) Compuestos de piridilo sustituidos con alquilamida útiles como moduladores de respuestas de il-12 e il-23 y/o ifnalfa
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
BR112017014341A2 (pt) método e sistema para tratamento, estabilização, ou redução da gravidade ou progressão de uma doença de fígado gorduroso não alcoólica, e, composição.
CL2015003731A1 (es) Inhibidores de bromodominios
CR20150517A (es) Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il) nicotinamida
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
CL2015002194A1 (es) Inhbidores de erk y sus usos
EA201691421A1 (ru) Гетероарилы и их применение
BR112017001162A2 (pt) métodos para tratar paramixovírus
BR112018006696A2 (pt) métodos e sistemas para obter óleo a partir de uma composição de vinhoto
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112019018124A2 (pt) composições e métodos para imunooncologia
DOP2018000057A (es) Composiciones biofarmacéuticas
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
EA202091989A1 (ru) Способы лечения язвенного колита
BR112017023225A2 (pt) inibidor de proteína cinase
CL2018001067A1 (es) Compuesto piranodipiridínico.
DK2988760T3 (da) C. novyi til behandlingen af faste tumorer i mennesker

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) ; ALCEDIAG (FR)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]